Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE) - 30/06/22
, J. Antonio G． López, MD b, Beat Knusel, PhD b, Baris Gencer, MD c, d, Huei Wang, PhD b, You Wu, PhD b, Helina Kassahun, MD b, Marc S. Sabatine, MD, MPH aAbstract |
Background |
Data support lipoprotein(a) (Lp[Lp(a)]) being a risk factor for atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that markedly reduces Lp(a) production in hepatocytes.
Study Design |
The Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study is a multicenter, randomized, double-blind, placebo-controlled dose-finding study in 281 subjects with established ASCVD and Lp(a) > 150 nmol/L. Patients were randomly allocated to one of 4 active subcutaneous doses of olpasiran (10 mg q12 weeks, 75 mg q12 weeks, 225 mg q 12 weeks, or 225 mg q24 weeks) or matched placebo. The primary objective is to evaluate the effects of olpasiran dosed every 12 weeks compared with placebo on the percent change in Lp(a) from baseline at 36 weeks. Enrollment is now complete and follow-up is ongoing.
Conclusions |
OCEAN(a)-DOSE trial is assessing the Lp(a)-lowering efficacy and safety of olpasiran. These data will be used to determine optimal dosing and design for a cardiovascular outcomes trial.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| ☆ | ClinicalTrials.gov identifier: NCT04270760. |
Vol 251
P. 61-69 - settembre 2022 Ritorno al numero
Articolo precedente
- A randomized multicenter trial to evaluate early invasive strategy for patients with acute ST-segment elevation myocardial infarction presenting 24-48 hours from symptom onset: Protocol of the RESCUE-MI study
- Wei Gao, Xin Zhong, Yuanji Ma, Dong Huang, Ruochen Wang, Shihai Zhao, Shan Yang, Juying Qian, Junbo Ge
- Rationale and design of switch Swedeheart: A registry-based, stepped-wedge, cluster-randomized, open-label multicenter trial to compare prasugrel and ticagrelor for treatment of patients with acute coronary syndrome
- Elmir Omerovic, David Erlinge, Sasha Koul, Ole Frobert, Jonas Andersson, Johan Ponten, Fredrik Björklund, Robert Kastberg, Max Petzold, Charlotta Ljungman, Kristian Bolin, Björn Redfors
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?